The efficacy and drug survival of the biosimilar infliximab (CT-P13) compared to the original reference infliximab in inflammatory rheumatic diseases results from the turkbio registry

USLU S., CAN G., ŞENEL S., DALKILIÇ H. E., İNANÇ G. N., AKAR S., ...Daha Fazla

EULAR2018, 13 - 16 Haziran 2018

  • Yayın Türü: Bildiri / Özet Bildiri
  • Marmara Üniversitesi Adresli: Evet